logo-loader
viewOpyl Ltd

Opyl confident revenue will level out and potentially improve in June quarter

The company is focused on developing digital tools that improve the healthcare experience for patients, deliver deep market insights from social media data and improve the efficiency and value of the clinical research process by employing artificial intelligence and emerging digital tools.

Opyl Ltd - Opyl confident revenue will level out and potentially improve in June quarter
Opyl recently received a $201,000 research and development tax refund

Opyl Ltd (ASX:OPL) had a closing cash balance of $137,000 for the March quarter, with an overall revenue of $188,000 , down $76,000 from the previous quarter.

Some revenue decrease was seasonal through the January period as well as changes to payment schedules.

On the whole, reduced revenues were a result of the shift of focus to business development within larger pharma and medtech companies (which take longer to secure as clients at a higher price point) and the investment of time in laying a solid foundation of understanding with 'huumun' in preparing to pitch together.

However, the company anticipates that this will level out or improve as it becomes cash flow neutral through reduced expenditure, and income increases along with the company’s eligibility for R&D tax incentive and COVID19 business support payments.

Huumun partnership

A highlight during the quarter included the announcement of a revenue-share alliance with UK-based huumun, a digital solution provider for the global pharma sector.

The collaboration allows the two companies to provide an extended, sophisticated end-to-end sales and marketing offering across traditional and digital platforms.

This is anticipated to realise revenue for Opyl in the coming months and will create a valuable business development pipeline – improving the company’s chances of client acquisition and hitting revenue goals this financial year.

COVID-19 impacts

The COVID19 environment has had both a positive and negative influence on Opyl.

The company is currently seeing a marked increase in interest from prospective clients, (over and above the huumun business development effort), validating the role of digital, particularly social media to organisations when their sales teams are grounded.

The use of social media in a healthcare context has also increased due to physical distancing and the need to access and share information around the globe – which social media does so well.

The timing of client payments has been arriving later than normal in the past six months and while retainer-based client revenue remains constant, COVID-19 has had an influence on some accounts.

Future focus

The company has continued to invest in its research platforms during the March quarter.

The focus is on developing a machine learning, artificial intelligence-based software interface which can predict the likelihood of a clinical trial completing each phase.

To date, the clinical trial predictor tool has been progressed to the end of stage two (proof of concept) in readiness to enter stage three and finally stage four before calendar year-end.

Quick facts: Opyl Ltd

Price: 0.1 AUD

ASX:OPL
Market: ASX
Market Cap: $3.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Opyl is new name of digital health track company ShareRoot

Opyl Limited (ASX:OPL) chief executive officer Michelle Gallaher updates Proactive on the renaming of the global digital health track company formerly known as ShareRoot Ltd (ASX:SRO). This heralds the company’s entry into the rapidly expanding global digital health and artificial...

on 9/12/19

2 min read